Anticancer activities of novel chalcone and bis-chalcone derivatives

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 10, 2006, Pages 3491-3495

  Modzelewska, Aneta ^a   Pettit, Catherine ^a   Achanta, Geetha ^b   Davidson, Nancy E ^a   Huang, Peng ^b   Khan, Saeed R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer; Bis chalcone; Chalcone; Claisen Schmidt reaction

Indexed keywords

1 (PHENYL 4 BORONIC ACID) 3 THIOPHEN 2 YLPROPENONE; 2 (4 CHLOROBENZOYL) 3 (4 HYDROXYPHENYL)PROPENONE; 3 (4 CHLOROPHENYL) 1 (4 HYDROXYPHENYL)PROPENONE; 3 (4 CHLOROPHENYL) 1 (PHENYL 4 HYDROXYMETHYLBORONIC ACID)PROPENONE; 3 BENZO[B]THIOPHEN 2 YL 1 (PHENYL 4 BORONIC ACID)PROPENONE; 3,5 BIS(4 BORONIC ACID BENZYLIDENE) 1 METHYLPIPERIDIN 4 ONE; 3,5 BIS(4 CHLOROBENZYLIDENE) 1 METHYLPIPERIDIN 4 OL; 3,5 BIS(4 CHLOROBENZYLIDENE) 1 METHYLPIPERIDIN 4 ONE; 4 TERT BUTYL 2,6 BIS(4 BORONIC ACID BENZYLIDENE)CYCLOHEXANOL; 4 TERT BUTYL 2,6 BIS(4 BORONIC ACID BENZYLIDENE)CYCLOHEXANONE; BENZOIC ACID 3,5 BIS(4 CHLOROBENZYLIDENE) 1 METHYLPIPERIDIN 4 YL ESTER; CHALCONE; CHALCONE DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SYNTHESIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; NULL ALLELE; PROTEIN EXPRESSION; WILD TYPE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHALONES; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LETHAL DOSE 50; MOLECULAR STRUCTURE; PIPERIDINES;

MINK CELL FOCUS-FORMING VIRUS;

EID: 33645885368     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.01.003     Document Type: Article

References (17)

1. Won S.-J., Liu C.-T., Tsao L.-T., Weng J.-R., Ko H.-H., Wang J.-P., and Lin C.-N. Eur. J. Med. Chem. 40 (2005) 103
2. Hsieh H.-K., Tsao L.-T., Wang J.-P., and Lin C.-N. J. Pharm. Pharm. 52 (2000) 163
3. Lin, C.-N.; Wang, J.-P. U.S. Patent, Appl. Publ. 2004, 13 pp.
4. De Leon E.J., Alcaraz M.J., Dominguez J.N., Charris J., and Terencio M.C. Inflamm. Res. 52 (2003) 246
5. Mukherjee S., Kumar V., Prasad A.K., Raj H.G., Bracke M.E., Olsen C.E., Jain S.C., and Parmar V.S. Bioorg. Med. Chem. 9 (2001) 337
6. Parmar V.S., Jain S.C., Bisht K.S., Sharma N.K., Himanshu, Gupta S., Prasad A.K., Jha A., Poonam, Malhotra S., Sharma S.K., Bracke M.E., Errington W., Olsen C.E., and Wengel J. Indian J. Chem., Sect. B 37 (1998) 628
7. Lin, Y. M.; Zhou, Y. Flavin, M. T.; Zhou, L.M.; Nie, W. PCT Int. Appl. 2003, 121 pp.
8. Chen F.-C. Bioorg. Med. Chem. 10 (2002) 2795
9. Saydam G., Aydin H.H., Sahin F., Kucukoglu O., Erciyas E., Terzioglu E., Buyukkececi F., and Omay S.B. Leuk. Res. 27 (2003) 57
10. Kumar S.K., Hager E., Pettit C., Gurulingappa H., Davidson N.E., and Khan S.R. J. Med. Chem. 46 (2003) 2813
11. Myung J., Kim K.B., and Crews C.M. Med. Res. Rev. 21 (2001) 245
12. Wang W., Gao X., and Wang B. Curr. Org. Chem. 6 (2002) 1285
13. Soloway A.H., Tjarks W., Barnum B.A., Rong F.-G., Barth R.F., Codogni I.M., and Wilson G. Chem. Rev. 98 (1998) 1515
14. Dinkova-Kostova A.T., Massiah M.A., Bozak R.E., Hicks R.J., and Talalay P. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3404
15. Adams B.K., Ferstl E.M., Davis M.C., Herold M., Kurtkaya S., Camalier R.F., Hollingshead M.G., Kaur G., Sausville E.A., Rickles F.R., Snyder J.P., Liott D.C., and Shoji M. Bioorg. Med. Chem. 12 (2004) 3871
16. Daskiewicz J.B., Comte G., Barron D., Di Petro A., and Thomason F. Tetrahedron Lett. 40 (1999) 7095
17. Mosmann T. J. Immunol. Methods 65 (1983) 55